Actively Recruiting
Study of 68Ga-R10602
Led by Radionetics Oncology · Updated on 2026-03-13
36
Participants Needed
6
Research Sites
81 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A phase 1 imaging study of 68Ga-R10602 in hormone-receptor positive breast cancer.
CONDITIONS
Official Title
Study of 68Ga-R10602
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathologically confirmed ER and/or PR positive, locoregionally recurrent or metastatic breast cancer refractory to endocrine therapy with at least one prior line of chemotherapy or antibody drug conjugate for Population 1
- ER positive and HER2 negative locoregional or metastatic breast adenocarcinoma progressing on at least one line of prior endocrine therapy and starting next endocrine therapy for Population 2
- ER and/or PR positive and HER2 negative breast adenocarcinoma for Population 3 if ineligible for Populations 1 or 2
- At least one target or non-target lesion per RECIST 1.1
- Male or non-pregnant, non-lactating female aged 18 years or older
- Female of child-bearing potential and sexually active male must agree to use effective contraception during the study
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2
- Adequate liver function within 28 days before dosing
- Adequate renal function (creatinine clearance ≥60 mL/min) within 28 days before dosing
- Able to understand and sign informed consent form
You will not qualify if you...
- Received radionuclide within less than 10 physical half-lives before dosing
- Radiotherapy within 14 days before dosing
- Major surgery within 21 days before dosing or not recovered from surgery effects
- Severe or unstable medical conditions such as advanced heart failure, ischemic heart disease, uncontrolled hypertension or diabetes, significant cardiac arrhythmia, recent myocardial infarction, or other unstable cardiac illness
- History of cerebrovascular accident within 6 months or ongoing neurologic instability
- Major active infection requiring antibiotics
- Known active HIV infection or active Hepatitis B or C infection
- Acute illness within 14 days before dosing unless mild
- Any other condition that poses unacceptable risk or limits study participation or compliance
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
UCLA Department of Medicine - Hematology/Oncology
Los Angeles, California, United States, 90095
Actively Recruiting
2
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States, 46202
Actively Recruiting
3
University of Iowa
Iowa City, Iowa, United States, 52242
Actively Recruiting
4
University of Michigan Medicine
Ann Arbor, Michigan, United States, 48109
Actively Recruiting
5
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
6
University of Utah, Huntsman Cancer Institute
Salt Lake City, Utah, United States, 844112
Actively Recruiting
Research Team
Y
Yael Cohen-Arazi
CONTACT
K
Kristrun Stardal
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here